BioSpace News Archive

Inventiva reported certain preliminary unaudited financial results as of and for the full year ended December 31, 2023, including cash, cash equivalents, and revenues, and provided an update on its clinical trial NATiV3.

Agile Therapeutics, Inc. announced it has been granted an extension by Nasdaq to regain compliance with the stockholders’ equity requirement for continued listing and provided performance update for full year 2023.

Profound Medical Corp. will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024.

GE HealthCare Technologies Inc. announced the launch of a secondary underwritten public offering of 13,000,000 shares of its common stock.

Avidity Biosciences, Inc. announced that the company will be presenting multiple posters from all three clinical development programs in rare muscle diseases, including new AOC 1001 long-term efficacy and safety data from the MARINA open-label extension trial in people living with myotonic dystrophy type 1 at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida.

Aeterna Zentaris Inc. announced that it has issued a Letter to Shareholders and Management Proxy Circular ahead of its special meeting of shareholders to approve its merger of equals transaction with Ceapro Inc.

Sirona Biochem Corp. announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 with 0906462 B.C. Ltd.

Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, announced the availability of Shield Standard, which combines a fish-skin graft and silicone backing for efficient treatment of acute and chronic wounds.

Genomma Lab Internacional, S.A.B. de C.V., one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, provides a preliminary overview of 2023 full year performance relative to hyperinflationary accounting for its Argentina subsidiary.

Sosei Group Corporation, announces that at a meeting held on 15 February 2024, its Board of Directors resolved to change the corporate names of the Company and its subsidiaries and the location of the head office of the Company.